Abstract:Objective:To prospectively observe the clinical efficacy and safety of corticosteroids in combination with mycophenolate mofetil dispersible tablets(Cicopin~,MMF,Hangzhou Zhongmei Huadong pharmaceutical Co,Ltd) and tacrolimus(FK506,Hangzhou Zhongmei Huadong pharmaceutical Co,Ltd)(multi-target group) in the induction treatment for lupus nephritis(LN).Methodology:Seventy-nine patients with biopsy confirmed class IV,V+IV and V+III LN were randomly assigned to either multi-target group [n=45,39 females,6 males,mean age(25.1±9.3) years] or intravenous cyclophosphamide pulse therapy(IV-CYC) [n=34,30 females,4 males,mean age(30.4±8.9) years].All patients received intravenous methylprednisolone pulse therapy followed by oral prednisone.In multi-target group,the dose of MMF and FK506 was adjusted based on the blood level with the MPA-AUC0～12h level of 20～30 mg o h/L and FK506 trough level 4～7 ng/ml.In IV-CYC group,CYC was given in a dose 0.5～0.75 g/m2BSA monthly.The induction period was 6months to 9 months according to the responses on the therapy.The primary efficacy parameter was complete remission rate(defined as urine protein 0.4 g/24h,serum albumin ≥35 g/l,normal serum creatinine and no extra-renal activity),the secondary parameters were partial remission rate(defined as urinary protein less than the base value of 50% or more,and urine protein 3.5 g/24h,serum albumin ≥30 g/l,and serum creatinine stable) and incidence of adverse reactions.The clinical efficacy and adverse events were compared between two groups.Results:The baseline clinical and histological classes had no significant differences between multi-target group and IV-CYC group.The accumulated complete remission rate of multi-target group was significantly higher than that of IV-CYC group(P0.05) during the induction period.At 6months and 9 months,the complete remission rate was 53.3% and 62.2% respectively in the multi-target group,and 29.4% and 42.6%,in IV-CYC group respectively.Also,multi-target therapy showed much higher complete remission rate than IV-CYC therapy for class V+IV(50.0% vs 16.7%,P0.05) and class V+III(54.5% vs 22.2 %,P0.05).In class IV LN,no difference of the remission rate was found between the two groups.The incidence of adverse events in the multi-target group was much lower than that in the IV-CYC group(31.1% vs 70.6%,P0.01),the major adverse events were new-onset hypertension(11.1%) and herpes zoster(6.7%) in the multi-target group;while gastrointestinal reactions(23.5%),leukopenia(13.7%) and skin infections(8.8%) in the IV-CYC group.Three patients(2 in multi-target group and 1 in IV-CYC group) complicated with pulmonary infection,but none died.Conclusion:The multi-target therapy,which is composed of corticosteroids with Cicopin and tacrolimus,showed more effective than intravenous CYC pulse therapy in inducing remission of lupus nephritis,especially class V+IV,and had a more favorable safety.However,multi-center clinical trials are encouraged to evaluate the clinical efficacy and the impact on long-term survival for lupus nephritis.

Combined Therapy of Mycophenolate Mofetil and Prednisone for Refractory Lupus Nephritis

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome.

Evaluation of the efficacy of mycophenolate mofetil treatment in lupus nephritis

Combined treatment of small dose corticosteroids and mycophenolate mofetil for lupus nephritis

Treatment of Refractory Nephropathy in Children with Mycophenolate Mofetil

Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study.

Mycophenolate Mofetil in the Treatment of Primary Nephrotic Syndrome

A Prospective Study of Multi-Target Therapy on Refractory Lupus Nephritis

Efficacy and long-term prognosis of mycophenolate mofetil treatment on patients with proliferative lupus nephritis

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Three-year Follow-up Study of Lupus Nephritis Treated with Mycophenolate Mofetii

Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide for Class Ⅳ Plus Ⅴ Lupus Nephritis

Mycophenolate mofetil combined with low dose prednisone in the treatment for adults with minimal change nephrotic syndrome and concomitant HBsAg positive

Mycophenolate Mofetil Treatment for Diffuse Proliferative Lupus Nephritis: a Multicenter Clinical Trial in China.

Clinical study of mycophenolate mofetil therapy versus intermittent cyclophosphamide pulse treatment in lupus nephritis

A Prospective Preliminary Study of Tacrolimus (FK506) Combined with Low-Dose Prednisone in Patients with Membranous Lupus Nephropathy

A Prospective Clinical Trail of Corticosteroids in Combination with Mycophenolate Mofetil Dispersible Tablets and Tacrolimus for the Induction Treatment of Lupus Nephritis

A randomized control trail of leflunomide and mycophenolate mofeil treatment in refractory nephropathy syndrome

Mycophenolate Mofetil for Proliferative Lupus Nephritis: A Systematic Review

Efficacy and Safety of Treatment with Combine Mycophenolate Mofetil and Corticosteroid for Lupus Nephritis:A Multicenter Open-label Study